FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

Guide on REMS Logic Model

Federal Register notice: FDA makes available a draft guidance entitled REMS Logic Model: A Framework to Link Program Design With Assessment.

latest-news-card-1
Human Drugs

House Committee Pressures FDA on China Oversight

The House Oversight Committee puts pressure on FDA and its oversight of imported Chinese and other foreign active pharmaceutical ingredients and finis...

latest-news-card-1
Human Drugs

Bioresearch Monitoring Violations at DBC Research

FDA warns Dr. Kevin Bender, doing business as DBC Research in Tamarac, FL, about violations in his conduct of clinical trials.

latest-news-card-1
Human Drugs

Endo Paying $1.5 Billion Fines, Forfeitures

Endo is ordered to pay $1.85 billion in fines and forfeitures after pleading guilty to introducing misbranded Opana ER into interstate commerce and cl...

latest-news-card-1
Medical Devices

Multiple Violations in Bioptimal Inspection

FDA warns Chinas Bioptimal International about multiple violations at a Singapore facility manufacturing two unapproved catheters.

latest-news-card-1
Medical Devices

CDRH Product Evaluation/Quality Office Modified

Federal Register notice: FDA announces that CDRH Office of Product Evaluation and Quality has modified its organizational structure.

latest-news-card-1
Human Drugs

FDA OKs TE Code for Paclitaxel Suspension

FDA approves an AB therapeutic equivalence code for cancer drug paclitaxel suspension and tells HBT Labs it must formally apply for a return of PDUFA ...

latest-news-card-1
Federal Register

FDA Debars Runsdorg Over Cough Syrup

Federal Register notice: FDA issues an order permanently debarring Adam Paul Runsdorf over his felony conviction for conspiring to distribute counterf...

latest-news-card-1
Human Drugs

CDER Launches Quantitative Medicine Center

CDER launches a new Quantitative Medicine Center of Excellence to help streamline and accelerate drug development.

latest-news-card-1
FDA General

J&J Reports Favorable TAR-200 Clinical Data

A Phase 2b clinical study evaluating Johnson & Johnsons investigational TAR-200 monotherapy in nonmuscle-invasive bladder cancer patients with carcino...